Dendreon Extends Provenge Supply In Agreement With GSK
This article was originally published in The Pink Sheet Daily
Supply arrangement won't impact availability of Provenge this year; first shipment from GSK will begin in 2011, according to a regulatory filing.
You may also be interested in...
Dendreon gave an update on the launch of the prostate cancer vaccine during its earnings call on Aug. 3.
The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.
Having gotten over the hurdle of FDA approval with the market's first therapeutic cancer vaccine, Dendreon now faces the challenge of getting Provenge to the market. Already the company is also signaling that supply is unlikely to match demand in the near term